Meeting
2022 ASCO Annual Meeting
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
Authors
Julie R. Brahmer
Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, MD
Julie R. Brahmer , Jong-Seok Lee , Tudor-Eliade Ciuleanu , Reyes Bernabe Caro , Makoto Nishio , Lazlo Urban , Clarisse Audigier-Valette , Lorena Lupinacci , Randeep S. Sangha , Luis G. Paz-Ares , Martin Reck , Hossein Borghaei , Kenneth John O'Byrne , Ravi Gupta , Judith Bushong , Li Li , Steven I. Blum , Laura Eccles , Suresh S. Ramalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02477826
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA9025)
DOI
10.1200/JCO.2022.40.17_suppl.LBA9025
Abstract #
LBA9025
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
First Author: Luis G. Paz-Ares
Poster
2021 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
First Author: Luis G. Paz-Ares
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2018 ASCO Annual Meeting
Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
First Author: Martin Reck